Given our strong interest in the pre-clinical development of engineered T cells for cancer immunotherapy using syngeneic tumor models, we next compared the efficacy of the differently configured vectors (targeting CD25, CD45, and CD54) in primary murine OT-I CD8+ T cells [22, 44]. The gene discussed is PTPRC; the disease is neoplasm.